Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros

Bases de datos
Tipo del documento
Intervalo de año de publicación
1.
Cell Metab ; 22(5): 761-76, 2015 Nov 03.
Artículo en Inglés | MEDLINE | ID: mdl-26365177

RESUMEN

Alzheimer's disease (AD) is increasingly recognized as a complex neurodegenerative disease beginning decades prior to the cognitive decline. While cognitive deficits remain the cardinal manifestation of AD, metabolic and non-cognitive abnormalities, such as alterations in body weight and neuroendocrine functions, are also present, often preceding the cognitive decline. Furthermore, hypothalamic dysfunction can also be a driver of AD pathology. Here we offer a brief appraisal of hypothalamic dysfunction in AD and provide insight into an underappreciated dual role of the hypothalamus as both a culprit and target of AD pathology, as well as into new opportunities for therapeutic interventions and biomarker development.


Asunto(s)
Enfermedad de Alzheimer/metabolismo , Biomarcadores/metabolismo , Cognición , Células Neuroendocrinas/metabolismo , Enfermedad de Alzheimer/patología , Péptidos beta-Amiloides/metabolismo , Animales , Peso Corporal , Modelos Animales de Enfermedad , Humanos , Hipotálamo/metabolismo , Hipotálamo/patología , Células Neuroendocrinas/patología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA